title: Plasma tumor necrosis factor-alpha, its soluble receptors and interleukin-1beta levels in critically burned patients.
abstract: Levels of plasma TNF-alpha, interleukin-1beta(IL-1beta ), soluble TNF-receptor I (sTNF-R I) and soluble TNF-receptor II (sTNF-R II) were determined in 16 critically burned patients. Seven of the 16 patients showed hypovolemic shock (shock group), 9 with sepsis (sepsis group), 8 with multiple organ dysfunction syndrome (MODS group) and 6 of them died (non-survival group). Plasma TNF-alpha, sTNF-R I and R II were significantly higher in the shock group, the MODS group and the non-survival group than each of the control groups. TNF-alpha and sTNF-Rs increased gradually in the MODS group and the non-survival group from 1 to 5 days postburn. TNF-alpha, sTNF-R I and R II correlated positively with Goris' multiple organ failure score. Molecular sTNF-Rs/TNF-alpha ratios were lower in the sepsis group than in the non-sepsis group. These results suggest that circulating TNF and soluble TNF receptors system play an important role in the development of burn shock and MODS; high molecular ratios of endogenous sTNF-Rs might not reduce the morbidity of MODS and the mortality in critically burned patients.
authors.affiliation: Burn Center, Central Hospital Affiliated to Shenyang Medical College, People's Republic of China. bzhang@pub.ln.cninfo.net
authors.forename: B
authors.initials: B
authors.lastname: Zhang
authors.forename: Y H
authors.initials: YH
authors.lastname: Huang
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.forename: Z L
authors.initials: ZL
authors.lastname: Hao
authors.forename: S L
authors.initials: SL
authors.lastname: Xie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002056:Burns / Q000097:blood* / Q000150:complications / Q000401:mortality; D016638:Critical Illness; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007375:Interleukin-1 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000097:blood / Q000209:etiology / Q000401:mortality; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood*; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D018805:Sepsis / Q000097:blood / Q000209:etiology / Q000401:mortality; D012774:Shock, Traumatic / Q000097:blood / Q000209:etiology / Q000401:mortality; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D015415:Biomarkers; D007375:Interleukin-1; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha